All articles tagged with #tagrisso
AstraZeneca's FLAURA2 Phase III trial shows that combining Tagrisso with chemotherapy significantly improves overall survival in patients with EGFR-mutated advanced non-small cell lung cancer, reinforcing Tagrisso as a key treatment option across stages.
AstraZeneca's drug Tagrisso significantly reduces the progression of stage 3 lung cancer by 84% in patients with a specific genetic mutation, potentially changing treatment practices according to experts at the American Society of Clinical Oncology.
A five-year study published in The New England Journal of Medicine has shown that the lung cancer pill, Osimertinib (Tagrisso), can reduce the risk of recurrent cancer by up to 73% and the risk of death by up to 51% in patients with Stage 1B-3A lung cancer who have a certain genetic mutation and have had surgery to remove cancerous tumors. The results have been described as "earth-shattering" by experts in the field, as the improvement in survival rates far exceeds previous expectations. The pill is part of the growing field of personalized medicine, targeting specific genetic mutations in tumors, and offers hope for lung cancer patients who were previously considered to have a fatal disease.
A medication called Osimertinib, sold under the brand name Tagrisso, has shown "earth-shattering" results in a five-year study for lung cancer patients with a certain genetic mutation. The study found that Tagrisso reduced the risk of recurrent cancer by up to 73% and the risk of death by up to 51%. This targeted therapy is available to patients with Stage 1B-3A lung cancer who have had surgery to remove cancerous tumors and have the EGFR mutation. The medication aims to prevent recurrence and improve survival rates, offering hope to patients who previously faced a fatal disease.
AstraZeneca's lung cancer drug, Tagrisso, has been found to reduce the risk of death by over 50% in patients with early-stage non-small cell lung cancer (NSCLC) who have undergone surgery to remove their primary tumor. The drug was evaluated against a placebo in a 682-patient trial called ADAURA. The trial data establishes Tagrisso as the backbone treatment for EGFR-mutated lung cancer. The drug has already received regulatory approvals across multiple geographies for certain patients with NSCLC who have a mutation of the EGFR gene.
AstraZeneca's lung cancer drug, Tagrisso, has been found to reduce the risk of death by over 50% in patients with early-stage non-small cell lung cancer (NSCLC) who have undergone surgery to remove their primary tumor. The drug was evaluated against a placebo in a 682-patient trial called ADAURA, and the data showed that Tagrisso slashed the risk of death by 51% compared to placebo. The drug is already approved for certain patients with NSCLC who have a mutation of the EGFR gene and is expected to become the backbone treatment for EGFR-mutated lung cancer.
AstraZeneca's Tagrisso-chemo combination has shown statistically significant and clinically meaningful improvement in progression-free survival compared to Tagrisso as a monotherapy in late-stage lung cancer patients, according to the Phase III FLAURA2 trial. The trial tested the combination in late-stage patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer.